AbbVie Presents Data at the 64th American Society of Hematology (ASH) Annual Meeting for Investigational Navitoclax in Combination With Ruxolitinib for JAK Inhibitor-Naïve Myelofibrosis Patients ...Middle East

Exploratory analysis from Cohort 3 of the Phase 2 REFINE study presented in an oral session at ASH NORTH CHICAGO, Ill., Dec. 10, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced new data from Cohort 3 of its Phase 2 REFINE study of investigational navitoclax in combination with...

Hence then, the article about abbvie presents data at the 64th american society of hematology ash annual meeting for investigational navitoclax in combination with ruxolitinib for jak inhibitor naive myelofibrosis patients was published today ( Saturday 10/12/2022 - 11:17 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( AbbVie Presents Data at the 64th American Society of Hematology (ASH) Annual Meeting for Investigational Navitoclax in Combination With Ruxolitinib for JAK Inhibitor-Naïve Myelofibrosis Patients )

Also on site :

• General manager position restricted to only Saudis; Qiwa clarifies
• The NFL Names Its First-Ever 'Chief Kindness Officer' Ahead of Super Bowl LX
• Lady Gaga Pauses Tokyo Concert to Condemn ICE and Support Americans ‘Who Are Being Mercilessly Targeted’: ‘We Need to Get Back to a Place of Safety’